[CVM] Cel-Sci Corporation

Overview

Type of security: Stock

Sector: Health Care

Industry: Biotechnology: Biological Products (No Diagnostic Substances)

Market Capitalization:

Exchange: AMEX

The data is delayed by 15 minutes.

 

Price: 0.08 Change: -0.01 (-13.39%)
Ext. hours: 0.08 Change: 0 (0%)

chart CVM

Refresh chart

Strongest Trends Summary For CVM

CVM is in the long-term up 1080% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: CEL-SCI Corporation is engaged in the research and development of drugs and vaccines. The company?s lead investigational immunotherapy is Multikine, which is under pivotal phase III clinical trial for the treatment of primary head and neck cancer. Multikine is also being used in a Phase I study with the Naval Medical Center, San Diego under a cooperative research and development agreement in HIV/HPV co-infected men and women with peri-anal warts. In addition, it is developing Ligand Epitope Antigen Presentation System (LEAPS), a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune, allergies, transplantation rejection, and cancer. The company, through its LEAPS technology, is developing a peptide treatment for H1N1 hospitalized patients; and CEL-2000, a rheumatoid arthritis vaccine. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 1137.5% Sales Growth - Q/Q44.53% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-236.26% ROE-8765.89% ROI-337.3%
Current Ratio1.55 Quick Ratio1.12 Long Term Debt/Equity4.25 Debt Ratio10.73
Gross Margin Operating Margin-7915.99% Net Profit Margin-7175.9% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities6.4 M Cash From Investing Activities-60 K Cash From Operating Activities-12.24 M Gross Profit
Net Profit-12.56 M Operating Profit-7.76 M Total Assets12.73 M Total Current Assets5.7 M
Total Current Liabilities3.68 M Total Debt1.12 M Total Liabilities12.38 M Total Revenue200 K
Technical Data
High 52 week4.26 Low 52 week0.83 Last close2.83 Last change-1.74%
RSI47.37 Average true range0.12 Beta0.58 Volume4.05 M
Simple moving average 20 days-0.14% Simple moving average 50 days0.35% Simple moving average 200 days6.34%
Performance Data
Performance Week2.54% Performance Month4.81% Performance Quart0% Performance Half84.97%
Performance Year57.22% Performance Year-to-date-1.39% Volatility daily1.76% Volatility weekly3.94%
Volatility monthly8.08% Volatility yearly27.98% Relative Volume100.03% Average Volume240.41 K
New High New Low-15.44%

News

2019-06-11 16:35:28 | The Companies Set To Join The Russell Index July 1

2019-06-10 09:00:00 | CEL-SCI Corporation Set to Join Russell 3000® Index

2019-06-03 09:00:00 | CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational

2019-05-29 13:00:00 | CVM: Second Quarter 2019 Results

2019-05-14 16:33:16 | Cel-Sci: Fiscal 2Q Earnings Snapshot

2019-05-14 16:20:00 | CEL-SCI Corporation Reports Second Quarter Fiscal 2019 Financial Results

2019-05-13 09:00:00 | CEL-SCI Presents New Data for Its LEAPS Vaccine in the Treatment of Rheumatoid Arthritis at the American Association of Immunologists 103rd Annual Meeting

2019-05-08 08:00:00 | CEL-SCI Corporation Releases Letter to Shareholders

2019-04-30 09:00:00 | CEL-SCI to Present at the ThinkEquity Conference

2019-03-29 09:00:00 | CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

2019-03-26 18:16:05 | SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of CEL-SCI Corporation

2019-03-25 08:12:00 | CEL-SCI Corporation Releases Letter to Shareholders

2019-03-07 11:00:00 | CEL-SCI Selected by National Institutes of Health to Showcase Its LEAPS Technology at BIO International Convention

2019-03-04 08:00:00 | CEL-SCI’s Scientific Article on Vaccines for Autoimmune Disease Published in Journal of Clinical & Cellular Immunology

2019-03-01 11:45:00 | CVM: Clinical Trials Update

2019-02-14 16:27:31 | Cel-Sci: Fiscal 1Q Earnings Snapshot

2019-02-14 16:05:00 | CEL-SCI Corporation Reports First Quarter Fiscal 2019 Financial Results

2019-02-07 09:00:00 | CEL-SCI to Present at 2019 BIO CEO & Investor Conference

2019-02-04 10:00:00 | CVM: CEL-SCI: Advancing with an Intent to Cure

2019-02-01 11:30:00 | LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

2019-01-23 09:20:00 | U.S. Patent Office Issues CEL-SCI Two Patents for Its LEAPS Vaccine Platform Technology

2019-01-15 08:00:00 | CEL-SCI Regains Full Listing Compliance with NYSE American

2018-12-20 09:00:00 | CEL-SCI Reports Fiscal 2018 Financial Results and Clinical & Corporate Developments

2018-11-23 08:55:00 | Investor Expectations to Drive Momentum within Cel-Sci, DGSE Companies, Veracyte, China Pharma, Barnwell Industries, and Silvercrest Asset Management Group — Discovering Underlying Factors of Influence

2018-10-23 08:30:00 | CEL-SCI Receives about $8 Million from Warrant Exercises

2018-10-16 10:55:00 | CVM: A New Solution in Head & Neck Cancer

2018-10-01 08:30:00 | Penny Stocks to Buy Using Technical Analysis for October 2018

2018-09-28 08:00:00 | CEL-SCI Announces Warrants to Expire on October 11, 2018

2018-09-24 10:30:00 | Deals Pile Up as Big Biotech Looks to Capitalize on the Growing Market

2018-09-14 09:00:00 | CEL-SCI Receives $5.4 Million from Warrant Exercises

2018-09-07 09:30:01 | Has Cel-Sci CVM Outpaced Other Medical Stocks This Year?

2018-09-05 09:00:00 | NIH Selects CEL-SCI’s LEAPS Rheumatoid Arthritis Vaccine for Commercialization Accelerator Program

2018-08-22 08:00:00 | Today's Research Reports on Trending Tickers: Sage Therapeutics and CEL-SCI

2018-08-21 10:00:00 | CEL-SCI Corporation Releases Letter to Shareholders

2018-08-17 08:00:00 | CEL-SCI Announces That the NYSE American Approves Plan

2018-08-15 08:30:00 | CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

2018-08-14 17:13:15 | Cel-Sci: Fiscal 3Q Earnings Snapshot

2018-08-14 16:33:00 | CEL-SCI Corporation Reports Third Quarter Fiscal Year 2018 Financial Results

2018-07-13 17:10:00 | CEL-SCI Reports on NYSE American Noncompliance Notice and Compliance Plan

2018-07-10 07:30:00 | New Catalysts Could Send This $3 Medical Device Stock to $9

2018-07-09 09:00:00 | CEL-SCI Corporation Issues Letter to Shareholders

2018-07-02 12:46:00 | CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering

2018-06-28 14:56:13 | 'The drug was not the problem:' Vienna biotech Cel-Sci wins lawsuit after delayed trial

2018-06-28 13:09:00 | CEL-SCI Announces $5 Million Registered Direct Offering

2018-06-27 10:51:00 | CEL-SCI Receives $2.1 Million from Warrant Exercises

2018-06-27 08:00:00 | Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health

2018-06-11 09:00:00 | CEL-SCI Corporation Issues Letter to Shareholders

2018-06-08 08:30:00 | U.S. Patent Office Allows New CEL-SCI Patents for LEAPS Vaccine Platform Technology

2018-06-05 08:00:00 | CEL-SCI to Present Today at the 8th Annual LD Micro Invitational

2018-05-30 16:15:00 | CEL-SCI Announces Reminder of Warrant Exercise Price